Extended Data Table 1 Summary of adverse events

From: Oncolytic DNX-2401 virotherapy plus pembrolizumab in recurrent glioblastoma: a phase 1/2 trial

  1. AE denotes adverse event, SAE denotes serious adverse event; frequency refers to patients reporting at least one adverse event (each patient is included once), treatment related include those classified as possibly, probably, or definitely related to DNX2401 + pembrolizumab.
Back to article page